CVS Health (NYSE:CVS) Given “Hold (C)” Rating at Weiss Ratings

Weiss Ratings restated their hold (c) rating on shares of CVS Health (NYSE:CVS) in a research report report published on Tuesday,Weiss Ratings reports.

A number of other research analysts have also issued reports on CVS. Morgan Stanley lifted their target price on CVS Health from $82.00 to $89.00 and gave the stock an “overweight” rating in a report on Tuesday. Wells Fargo & Company lifted their price target on CVS Health from $84.00 to $103.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 7th. Robert W. Baird raised CVS Health from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $71.00 to $82.00 in a research note on Thursday, August 14th. Barclays lifted their price target on CVS Health from $80.00 to $87.00 and gave the stock an “overweight” rating in a research note on Thursday, September 4th. Finally, Baird R W raised CVS Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, CVS Health currently has a consensus rating of “Moderate Buy” and an average price target of $81.05.

CVS Health Price Performance

NYSE:CVS opened at $79.67 on Tuesday. The business’s 50-day moving average price is $72.95 and its 200 day moving average price is $67.83. The firm has a market cap of $101.05 billion, a P/E ratio of 22.25, a PEG ratio of 0.87 and a beta of 0.60. CVS Health has a 52-week low of $43.56 and a 52-week high of $79.94. The company has a quick ratio of 0.62, a current ratio of 0.80 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS) last released its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.35. The firm had revenue of $98.92 billion for the quarter, compared to analyst estimates of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.CVS Health’s revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the company earned $1.83 earnings per share. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts predict that CVS Health will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be given a dividend of $0.665 per share. The ex-dividend date is Thursday, October 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 3.3%. CVS Health’s dividend payout ratio (DPR) is presently 74.30%.

Insider Activity

In other news, Director Anne A. Finucane sold 7,500 shares of CVS Health stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total transaction of $532,650.00. Following the completion of the sale, the director directly owned 22,156 shares in the company, valued at $1,573,519.12. The trade was a 25.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.22% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CVS Health

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of CVS Health by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock valued at $8,305,132,000 after buying an additional 2,063,737 shares during the last quarter. Dodge & Cox lifted its holdings in shares of CVS Health by 4.8% during the 1st quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock valued at $4,976,856,000 after buying an additional 3,353,223 shares during the last quarter. State Street Corp lifted its holdings in shares of CVS Health by 1.4% during the 2nd quarter. State Street Corp now owns 58,788,585 shares of the pharmacy operator’s stock valued at $4,055,237,000 after buying an additional 800,414 shares during the last quarter. Geode Capital Management LLC lifted its holdings in CVS Health by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 28,635,233 shares of the pharmacy operator’s stock worth $1,966,083,000 after purchasing an additional 675,824 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in CVS Health by 15.3% in the 2nd quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock worth $1,623,270,000 after purchasing an additional 3,118,626 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.